Pfizer Inc. (NYSE: PFE) continues to highlight groundbreaking research and next-generation therapies from its comprehensive Oncology portfolio at the European Society for Medical Oncology (ESMO) Congress 2024, held from September 13-17 in Barcelona. The company will present data from over 50 abstracts, including more than 10 oral and mini-oral presentations, showcasing its advancements across various tumor types and core scientific approaches, including a potential treatment for a cancer-related condition.
“At ESMO 2024, we’re excited to demonstrate our progress in delivering next-generation biologics and innovative combinations that could set new standards of care for patients,” said Chris Boshoff, Chief Oncology Officer and Executive Vice President, Pfizer. “Our key presentations underscore Pfizer’s leadership in developing targeted therapies, including small molecules and antibody-drug conjugates, across key tumor areas such as breast, bladder, and thoracic cancers.”
Karin Tollefson, Chief Oncology Medical Officer at Pfizer, added, “We are eager to share important data that emphasize our commitment to transforming outcomes for patients with lung cancer, including long-term results from the BRAFTOVI + MEKTOVI PHAROS study in BRAF V600E-mutated metastatic non-small cell lung cancer. Additionally, we’ll provide updates on our pipeline of new molecules, including promising early results for two investigational antibody-drug conjugates and preliminary data on a novel combination of our next-generation CDK inhibitors.”
Among the key research highlights is a late-breaking presentation featuring updated data from the pivotal Phase 2 PHAROS* study of BRAFTOVI (encorafenib) + MEKTOVI (binimetinib) in patients with BRAF V600E-mutated metastatic non-small cell lung cancer (mNSCLC). These longer-term efficacy and safety results follow the primary overall response results (ORR) that led to FDA approval for this combination in 2023 and the European Commission approval in August 2024. Pfizer will also present new data from the safety lead-in of the ongoing Phase 3 BREAKWATER trial, demonstrating antitumor activity of BRAFTOVI + cetuximab + FOLFIRI in patients with untreated BRAF V600E-mutant metastatic colorectal cancer (mCRC) during a mini-oral session.
Pfizer will also present a late-breaking Proffered Paper on the Phase 2 efficacy and safety results for its GDF-15 inhibitor, ponsegromab, in cancer-associated cachexia, further reinforcing the company’s dedication to improving the treatment journey for cancer patients. Cancer cachexia is a severe and life-threatening condition characterized by extreme weight loss, commonly affecting patients with advanced cancer and negatively impacting their ability to tolerate treatment. Despite its severity, no FDA-approved treatments for cachexia currently exist.
In addition, Pfizer will share early-stage clinical research on several priority pipeline areas. This includes promising Phase 1 data for the first-in-class antibody-drug conjugate (ADC) candidate SGN-PDL1V (PF-08046054) in non-small cell lung cancer (NSCLC) and head and neck squamous cell carcinoma (HNSCC), initial results for the investigational ADC disitamab vedotin combined with KEYTRUDA ® (pembrolizumab) in HER2-expressing locally advanced or metastatic urothelial cancer, and the first data combining atirmociclib, Pfizer’s selective cyclin-dependent kinase 4 (CDK4) inhibitor, with a novel CDK2 inhibitor in hormone receptor-positive (HR+)/HER2-negative metastatic breast cancer from a Phase 1 dose-escalation study.
